Researchers from St. Louis University have developed a drug to target all types of cancer cells, while leaving healthy cells untouched.
Malignant cancer cells usually consume glucose by a different pathway than normal cells, giving them the energy to grow rapidly. This phenomenon is called the “Warburg effect.” This phenomenon makes sure that cancer cells get enough energy for their unrestricted growth.
Dr. Thomas Burris and his fellow researchers report that they have targeted this energy source with a drug and report that the Warburg effect is the metabolic foundation of cancer cell growth. Additionally, the team reports that Warburg effect also ensures tumor progression, metastasis, and resistance to treatment.
Dr. Burris tells to University of St. Louis News homepage, “Cancer cells look for metabolic pathways to find the parts to grow and divide. If they don’t have the parts, they just die,” said Burris. “The Warburg effect ramps up energy use in the form of glucose to make chemicals required for rapid growth and cancer cells also ramp up another process, lipogenesis, that lets them make their own fats that they need to rapidly grow.” Lipogenesis is the process of making fatty acids in cells and along with the Warburg effect, is key to cancer progression.
The drug that the team developed was initially meant for high cholesterol. SR9243, however, was found to:
According to Dr. Burris, “It works in a wide range of cancers both in culture and in human tumors developing in animal models. Some are more sensitive to it than others. In several of these pathways, cells had been reprogramed by cancer to support cancer cell growth. This returns the metabolism to that of more normal cells.”
If found effective in clinical trials, SR9243 could potentially be an effective drug that could arrest the growth of many types of cancer. It would be interesting to see if fasting, which negatively impacts Warburg effect, could also play a role in increasing the efficacy of SR9243.
Primary References:
(n.d.). Retrieved July 1, 2015, from http://www.slu.edu/x106658.xml
Flaveny, C., Griffett, K., El-Gendy, B., Kazantzis, M., Sengupta, M., Amelio, A., . . . Burris, T. (n.d.). Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis. Cancer Cell. doi:10.1016/j.ccell.2015.05.007
DoveMed Resources:
Sarkar, M. (n.d.). Can Fasting Make Less Toxic Cancer Drugs More Potent? Retrieved July 2, 2015.
and connect with fellow professionals
At DoveMed, our utmost priority is your well-being. We are an online medical resource dedicated to providing you with accurate and up-to-date information on a wide range of medical topics. But we're more than just an information hub - we genuinely care about your health journey. That's why we offer a variety of products tailored for both healthcare consumers and professionals, because we believe in empowering everyone involved in the care process.
Our mission is to create a user-friendly healthcare technology portal that helps you make better decisions about your overall health and well-being. We understand that navigating the complexities of healthcare can be overwhelming, so we strive to be a reliable and compassionate companion on your path to wellness.
As an impartial and trusted online resource, we connect healthcare seekers, physicians, and hospitals in a marketplace that promotes a higher quality, easy-to-use healthcare experience. You can trust that our content is unbiased and impartial, as it is trusted by physicians, researchers, and university professors around the globe. Importantly, we are not influenced or owned by any pharmaceutical, medical, or media companies. At DoveMed, we are a group of passionate individuals who deeply care about improving health and wellness for people everywhere. Your well-being is at the heart of everything we do.
0 Comments
Please log in to post a comment.